---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-003456"
form_type: "8-K"
ticker: null
cik: "0001349929"
company_name: "Vyant Bio, Inc."
filed_at: "2023-02-03T23:59:59+00:00"
generated_at: "2026-06-20T00:53:36.449067+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vyant Bio cuts workforce, CEO and CSO depart; CFO takes over as company seeks sale or wind-down

## Summary
- Board approved Cash Preservation Plan on Jan 31, including a reduction in force to retain only core employees.
- Estimated severance and termination costs of ~$1.4M in Q1 and Q2 2023; reductions expected by end of February.
- CEO John Roberts and CSO Robert Fremeau step down effective Feb 3; CFO Andrew LaFrence appointed President and CEO.
- Company continues to explore strategic alternatives with LifeSci Capital, including sale, merger, or orderly wind-down.
- Cash and cash equivalents ~$8.4M as of Jan 31, 2023; pre-clinical/clinical programs delayed or deferred.

## SEC filing metadata
- accession: 0001493152-23-003456
- form_type: 8-K
- cik: 0001349929
- company_name: Vyant Bio, Inc.
- filed_at: 2023-02-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-003456
- JSON: https://secwatch.observer/filing/0001493152-23-003456.json
- Plain text: https://secwatch.observer/filing/0001493152-23-003456.txt

## Key facts
- Executive change
  Robert T. Fremeau, Jr. departed as Chief Scientific Officer at Vyant Bio, Inc..
  - Action: step down
  - Role: Chief Scientific Officer
  source text: John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm
- Executive change
  John A. Roberts departed as President and Chief Executive Officer at Vyant Bio, Inc..
  - Action: step down
  - Role: President and Chief Executive Officer
  source text: John A. Roberts and Robert T. Fremeau, Jr., agreed in principle that Mr. Roberts and Dr. Fremeau would step down as President and Chief Executive Officer and Chief Scientific Officer, respectively, of the Company, effective as of February 3, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm
- Executive change
  Andrew D.C. LaFrence changed role as President and Chief Executive Officer at Vyant Bio, Inc..
  - Action: assume
  - Role: President and Chief Executive Officer
  source text: Andrew D.C. LaFrence, the Company’s Chief Financial Officer, will assume the role of President and Chief Executive Officer following Mr. Roberts’ departure.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm
- Restructurings & Charges
  Vyant Bio, Inc. announced a restructuring with charges of approximately $1.4 million.
  - Type: restructuring
  - Charge: approximately $1.4 million
  source text: the Board determined on January 31, 2023 to conduct a reduction in force as soon as practical, resulting in the retention of a core group of employees required for one or more potential strategic transactions and/or to execute an orderly wind down of the Company if required. The Company estimates that it will incur approximately $1.4 million for retention, severance and other employee termination-related costs in the first and second quarters of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1349929/000149315223003456/0001493152-23-003456-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.